BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou H, Jiang S, Chen J, Su SB. Suberoylanilide hydroxamic acid suppresses inflammation-induced neovascularization. Can J Physiol Pharmacol 2014;92:879-85. [PMID: 25272091 DOI: 10.1139/cjpp-2014-0117] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Hu Q, Zhang X, Sun M, jiang B, Zhang Z, Sun D. Potential epigenetic molecular regulatory networks in ocular neovascularization. Front Genet 2022;13:970224. [DOI: 10.3389/fgene.2022.970224] [Reference Citation Analysis]
2 Yang J, Ma Y, Luo Q, Liang Z, Lu P, Song F, Zhang Z, Zhou T, Zhang J. Improving the solubility of vorinostat using cyclodextrin inclusion complexes: The physicochemical characteristics, corneal permeability and ocular pharmacokinetics of the drug after topical application. Eur J Pharm Sci 2022;168:106078. [PMID: 34838620 DOI: 10.1016/j.ejps.2021.106078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Barry Z, Park B, Corson TW. Pharmacological Potential of Small Molecules for Treating Corneal Neovascularization. Molecules 2020;25:E3468. [PMID: 32751576 DOI: 10.3390/molecules25153468] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
4 Verza FA, Das U, Fachin AL, Dimmock JR, Marins M. Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy. Cancers (Basel) 2020;12:E1664. [PMID: 32585896 DOI: 10.3390/cancers12061664] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 23.5] [Reference Citation Analysis]
5 Li X, Yuan M, Yin R, Liu X, Zhang Y, Sun S, Han L, He S. Histone deacetylase inhibitor attenuates experimental fungal keratitis in mice. Sci Rep 2019;9:9859. [PMID: 31285488 DOI: 10.1038/s41598-019-46361-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
6 Elmallah MIY, Micheau O. Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy. Cancers (Basel) 2019;11:E850. [PMID: 31248188 DOI: 10.3390/cancers11060850] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
7 Roshandel D, Eslani M, Baradaran-Rafii A, Cheung AY, Kurji K, Jabbehdari S, Maiz A, Jalali S, Djalilian AR, Holland EJ. Current and emerging therapies for corneal neovascularization. Ocul Surf 2018;16:398-414. [PMID: 29908870 DOI: 10.1016/j.jtos.2018.06.004] [Cited by in Crossref: 68] [Cited by in F6Publishing: 74] [Article Influence: 17.0] [Reference Citation Analysis]
8 Liu X, Wang S, Wang X, Liang J, Zhang Y. Recent drug therapies for corneal neovascularization. Chem Biol Drug Des 2017;90:653-64. [DOI: 10.1111/cbdd.13018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
9 Zhang C, Yang C, Feldman MJ, Wang H, Pang Y, Maggio DM, Zhu D, Nesvick CL, Dmitriev P, Bullova P, Chittiboina P, Brady RO, Pacak K, Zhuang Z. Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. Oncotarget 2017;8:56110-25. [PMID: 28915577 DOI: 10.18632/oncotarget.18125] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 8.4] [Reference Citation Analysis]
10 Zhang C, Du L, Sun P, Shen L, Zhu J, Pang K, Wu X. Construction of tissue-engineered full-thickness cornea substitute using limbal epithelial cell-like and corneal endothelial cell-like cells derived from human embryonic stem cells. Biomaterials 2017;124:180-94. [PMID: 28199886 DOI: 10.1016/j.biomaterials.2017.02.003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
11 Yu J, Wu H, Lin Z, Su K, Zhang J, Sun F, Wang X, Wen C, Cao H, Hu L. Metabolic changes in rat serum after administration of suberoylanilide hydroxamic acid and discriminated by SVM. Hum Exp Toxicol 2017;36:1286-94. [PMID: 28084089 DOI: 10.1177/0960327116688067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
12 Bakunowicz-Łazarczyk A, Urban B. Assessment of therapeutic options for reducing alkali burn-induced corneal neovascularization and inflammation. Adv Med Sci 2016;61:101-12. [PMID: 26651127 DOI: 10.1016/j.advms.2015.10.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
13 Wang C, Balch WE. Managing the Adaptive Proteostatic Landscape: Restoring Resilience in Alpha-1 Antitrypsin Deficiency. Alpha-1 Antitrypsin 2016. [DOI: 10.1007/978-3-319-23449-6_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
14 Benito E, Urbanke H, Ramachandran B, Barth J, Halder R, Awasthi A, Jain G, Capece V, Burkhardt S, Navarro-Sala M, Nagarajan S, Schütz AL, Johnsen SA, Bonn S, Lührmann R, Dean C, Fischer A. HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models. J Clin Invest 2015;125:3572-84. [PMID: 26280576 DOI: 10.1172/JCI79942] [Cited by in Crossref: 128] [Cited by in F6Publishing: 135] [Article Influence: 18.3] [Reference Citation Analysis]
15 Chun P. Histone deacetylase inhibitors in hematological malignancies and solid tumors. Arch Pharm Res 2015;38:933-49. [PMID: 25653088 DOI: 10.1007/s12272-015-0571-1] [Cited by in Crossref: 77] [Cited by in F6Publishing: 65] [Article Influence: 11.0] [Reference Citation Analysis]